Katrina Podsypanina
First author of the study showing that an mTOR inhibitor reduced tumour growth and S6 kinase activity in Pten+/- mice; later moved from cancer genetics to tumour immunology
Postdoctoral researcher (Inserm), Bénédicte Manoury's team, Institut Necker Enfants Malades, Paris (since 2021) · Institut Curie, Paris · Program in Cancer Biology and Genetics, Memorial Sloan Kettering (Harold Varmus lab, about 2008) · Institute of Cancer Genetics, Columbia University (Ramon Parsons lab, about 1999–2001)
Katrina Podsypanina is first author of POD2001, from Ramon Parsons' group at Columbia University. In Pten+/- mice, transformed cells had more phosphorylated Akt and more active p70 S6 kinase. An mTOR inhibitor reduced neoplastic proliferation, tumour size and S6 kinase activity without changing Akt. The paper appeared next to NES2001 from Charles Sawyers' lab, which reached a matching conclusion in cell and xenograft models. She was also first author of a 1999 PNAS paper from the same group describing tumours in multiple organs of Pten-mutant mice.
She then worked in Harold Varmus' lab at Memorial Sloan Kettering, where a 2008 Science paper she led showed that untransformed mouse mammary cells placed in the bloodstream can settle in the lung and later grow into tumours once oncogenes are switched on. After a period at Institut Curie, she joined Bénédicte Manoury's team at the Institut Necker Enfants Malades in Paris in 2021, where she studies TLR9 signalling in dendritic cells and anti-tumour immunity.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2001 | A | An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice POD2001 First author: an mTOR inhibitor reduces neoplasia and normalises p70 S6 kinase activity in Pten+/- mice. |
Co-authors in the Atlas
People with a profile here who share at least one study with Katrina Podsypanina.
- Charles L. Sawyers Physician-scientist known for targeted cancer drugs (ABL inhibitors in leukaemia, antiandrogens in prostate cancer); his UCLA lab helped show that PTEN-deficient tumour cells depend more on mTOR
- John Blenis Showed early on that rapamycin blocks S6 kinase, then worked out how mTORC1 drives cell growth through its two main translation targets, S6K1 and 4E-BP1. His lab also found, in parallel with the Sabatini lab, that mTORC1 phosphorylates Grb10, a feedback brake on insulin signalling
- Ramon Parsons Cancer geneticist whose Columbia group identified the PTEN tumour suppressor gene in 1997, in parallel with another team; his lab then studied what goes wrong downstream of PTEN loss, including mTOR
Every researcher with a profile →
Thank you. Your answer was counted anonymously.
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.